β-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Gluschnaider, Udi ^a   Hidas, Guy ^a,b   Cojocaru, Gady ^a   Yutkin, Vladimir ^a,b   Ben Neriah, Yinon ^a   Pikarsky, Eli ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; AROMATIC HYDROCARBON RECEPTOR; BETA TRANSDUCIN REPEATS CONTAINING PROTEIN; F BOX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; DOXYCYCLINE; HOMEODOMAIN PROTEIN; RAG 1 PROTEIN; RAG-1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL PROLIFERATION; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; NUDE MOUSE; OVARIECTOMY; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSGENIC MOUSE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOXYCYCLINE; GENE EXPRESSION PROFILING; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TETRACHLORODIBENZODIOXIN; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 77949351362     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009060     Document Type: Article

References (49)

1. Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, et al. (2004) Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol 5: 303-313.
2. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
3. Coffey DS, Isaacs JT (1981) Control of prostate growth. Urology 17: 17-24.
4. Gao S, Lee P, Wang H, Gerald W, Adler M, et al. (2005) The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 19: 1792-1802.
5. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308.
6. Rahman M, Miyamoto H, Chang C (2004) Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 10: 2208-2219.
7. Rowland JG, Robson JL, Simon WJ, Leung HY, Slabas AR (2007) Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics 7: 47-63.
8. Setlur SR, Rubin MA (2005) Current thoughts on the role of the androgen receptor and prostate cancer progression. Adv Anat Pathol 12: 265-270.
9. Zhou P (2005) Targeted protein degradation. Curr Opin Chem Biol 9: 51-55.
10. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67: 425-479.
11. Maniatis T (1999) A ubiquitin ligase complex essential for the NF-kappaB, Wnt/ Wingless, and Hedgehog signaling pathways. Genes Dev 13: 505-510.
12. Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28: 613-619.
13. Fuchs SY, Spiegelman VS, Kumar KG (2004) The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23: 2028-2036.
14. Bhatia N, Thiyagarajan S, Elcheva I, Saleem M, Dlugosz A, et al. (2006) Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J Biol Chem 281: 19320-19326.
15. Ding Q, He X, Hsu JM, Xia W, Chen CT, et al. (2007) Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 27: 4006-4017.
16. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, et al. (2006) S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314: 467-471.
17. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, et al. (2003) Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 4: 799-812.
18. Kanemori Y, Uto K, Sagata N (2005) Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc Natl Acad Sci U S A 102: 6279-6284.
19. Li Y, Kumar KG, Tang W, Spiegelman VS, Fuchs SY (2004) Negative regulation of prolactin receptor stability and signaling mediated by SCF(beta-TrCP) E3 ubiquitin ligase. Mol Cell Biol 24: 4038-4048.
20. Liang C, Zhang M, Sun SC (2006) beta-TrCP binding and processing of NF-kappaB2/ p100 involve its phosphorylation at serines 866 and 870. Cell Signal 18: 1309-1317.
21. Nakayama KI, Nakayama K (2005) Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 16: 323-333.
22. Ray D, Osmundson EC, Kiyokawa H (2006) Constitutive and UV-induced fibronectin degradation is a ubiquitination-dependent process controlled by beta-TrCP. J Biol Chem 281: 23060-23065.
23. Tan M, Gallegos JR, Gu Q, Huang Y, Li J, et al. (2006) SAG/ROC-SCF beta-TrCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. Neoplasia 8: 1042-1054.
24. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, et al. (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9: 207-210.
25. Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, et al. (2004) Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer. J Natl Cancer Inst 96: 1161-1170.
26. Sadot E, Simcha I, Iwai K, Ciechanover A, Geiger B, et al. (2000) Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene 19: 1992-2001.
27. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, et al. (1998) Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 396: 590-594.
28. Chesire DR, Ewing CM, Gage WR, Isaacs WB (2002) In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21: 2679-2694.
29. Pearson HB, Phesse TJ, Clarke AR (2009) K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res 69: 94-101.
30. Cai Y, Wang J, Li R, Ayala G, Ittmann M, et al. (2009) GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression. Cancer Res 69: 819-827.
31. Nadiminty N, Chun JY, Lou W, Lin X, Gao AC (2008) NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 68: 1725-1733.
32. Zhang X, Huang X, Olumi AF (2009) Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells. Int J Cancer 124: 1980-1989.
33. Belaidouni N, Peuchmaur M, Perret C, Florentin A, Benarous R, et al. (2005) Overexpression of human beta TrCP1 deleted of its F box induces tumorigenesis in transgenic mice. Oncogene 24: 2271-2276.
34. Kudo Y, Guardavaccaro D, Santamaria PG, Koyama-Nasu R, Latres E, et al. (2004) Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol Cell Biol 24: 8184-8194.
35. Soldatenkov VA, Dritschilo A, Ronai Z, Fuchs SY (1999) Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. Cancer Res 59: 5085-5088.
36. Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, et al. (2005) Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res 65: 1904-1908.
37. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, et al. (2008) The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68: 6762-6769.
38. Barouki R, Coumoul X, Fernandez-Salguero PM (2007) The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 581: 3608-3615.
39. Marlowe JL, Puga A (2005) Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem 96: 1174-1184.
40. Bock KW, Kohle C (2006) Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. Biochem Pharmacol 72: 393-404.
41. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, et al. (2007) Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446: 562-566.
42. Fritz WA, Lin TM, Cardiff RD, Peterson RE (2007) The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 28: 497-505.
43. Frescas D, Pagano M (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8: 438-449.
44. Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, et al. (2006) Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25: 3436-3444.
45. Kizu R, Okamura K, Toriba A, Kakishima H, Mizokami A, et al. (2003) A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells. Arch Toxicol 77: 335-343.
46. Morrow D, Qin C, Smith R 3rd, Safe S (2004) Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J Steroid Biochem Mol Biol 88: 27-36.
47. Chesire DR, Dunn TA, Ewing CM, Luo J, Isaacs WB (2004) Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells. Cancer Res 64: 2523-2533.
48. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih Ie M, et al. (2002) APC/ CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34: 9-16.
49. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.